Deepsync Spółka z Ograniczoną Odpowiedzialnością (KRS 0001181699, NIP 5253052320) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. Deepsync operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since July 3, 2025. Deepsync's operations are currently suspended.
The company is currently suspended
Suspended since April 11, 2026
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Deepsync
Identity
- Name
- Deepsync Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- Limited Liability Company (LLC)
- Founded
- July 3, 2025
- Registry status as of
- July 15, 2026
- Latest entry
- July 15, 2026
- Founding act
- 01.07.2025
Articles of association history (1)
- July 1, 2025: 01.07.2025
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- ALEJA "SOLIDARNOŚCI", 117, 615, 00-140, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- NICK@DEEP-SYNC.EU
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-80171-57286-CTFJW-23
Operational status - Deepsync
Founded
July 3, 2025
1 year in operation
Legal form
Limited Liability Company (LLC)
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
5.0 K PLN
100 shares total
Shareholders
2
shareholders
Board
2 people
Registry entries
7
latest: July 15, 2026
Risk signals
No KPI data - financial statements and valuation are unavailable for this company.
Directories and rankings for this location
Public procurement
Trademarks
Reviews
Rate business credibility - Deepsync.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.